Daniel Sutherlin - Publications

1998- University of California, Berkeley, Berkeley, CA, United States 

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Sun S, Jia Q, Zenova AY, Wilson MS, Chowdhury S, Focken T, Li J, Decker S, Grimwood ME, Andrez JC, Hemeon I, Sheng T, Chen CA, White A, Hackos DH, ... ... Sutherlin DP, et al. Identification of selective acyl sulfonamide-cycloalkylether inhibitors of the voltage gated sodium channel (NaV) 1.7 with potent analgesic activity. Journal of Medicinal Chemistry. PMID 30499663 DOI: 10.1021/acs.jmedchem.8b01621  0.311
2018 Chernov-Rogan T, Li T, Lu G, Verschoof H, Khakh K, Jones SW, Beresini MH, Liu C, Ortwine DF, McKerrall SJ, Hackos DH, Sutherlin D, Cohen CJ, Chen J. Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 29311306 DOI: 10.1073/Pnas.1713701115  0.43
2017 Safina BS, Elliott RL, Forrest AK, Heald RA, Murray JM, Nonomiya J, Pang J, Salphati L, Seward EM, Staben ST, Ultsch M, Wei B, Yang W, Sutherlin DP. Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. Acs Medicinal Chemistry Letters. 8: 936-940. PMID 28947940 DOI: 10.1021/Acsmedchemlett.7B00170  0.308
2013 Safina BS, Sweeney ZK, Li J, Chan BK, Bisconte A, Carrera D, Castanedo G, Flagella M, Heald R, Lewis C, Murray JM, Nonomiya J, Pang J, Price S, Reif K, ... ... Sutherlin DP, et al. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity. Bioorganic & Medicinal Chemistry Letters. 23: 4953-9. PMID 23867164 DOI: 10.1016/J.Bmcl.2013.06.052  0.36
2013 Olivero AG, Heffron TP, Baumgardner M, Belvin M, Ross LB, Blaquiere N, Bradley E, Castanedo G, Derynck M, Do S, Dotson J, Dudley D, Edgar K, Folkes A, Francis R, ... ... Sutherlin D, et al. Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Ddt02-01  0.431
2012 Murray JM, Sweeney ZK, Chan BK, Balazs M, Bradley E, Castanedo G, Chabot C, Chantry D, Flagella M, Goldstein DM, Kondru R, Lesnick J, Li J, Lucas MC, Nonomiya J, ... ... Sutherlin DP, et al. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. Journal of Medicinal Chemistry. 55: 7686-95. PMID 22877085 DOI: 10.1021/Jm300717C  0.371
2012 Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, et al. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic & Medicinal Chemistry Letters. 22: 4296-302. PMID 22672799 DOI: 10.1016/J.Bmcl.2012.05.027  0.352
2012 Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH, Cartwright MW, Castanedo G, Chabot C, Cheguillaume AJ, Goldsmith P, Goldstein DM, Goyal B, Hancox T, Handa RK, ... ... Sutherlin DP, et al. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. Journal of Medicinal Chemistry. 55: 5887-900. PMID 22626259 DOI: 10.1021/Jm3003747  0.313
2011 Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, Heffron T, Lesnick J, Lewis C, Mathieu S, Murray J, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. Journal of Medicinal Chemistry. 54: 7579-87. PMID 21981714 DOI: 10.1021/Jm2009327  0.307
2008 Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D. On the edge of validation--cancer protease fibroblast activation protein. Mini Reviews in Medicinal Chemistry. 8: 719-27. PMID 18537727 DOI: 10.2174/138955708784567449  0.368
2006 Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W, Wolf BB. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. The Journal of Biological Chemistry. 281: 7437-44. PMID 16410248 DOI: 10.1074/jbc.M511112200  0.341
2006 Castanedo G, Clark K, Wang S, Tsui V, Wong M, Nicholas J, Wickramasinghe D, Marsters JC, Sutherlin D. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads. Bioorganic & Medicinal Chemistry Letters. 16: 1716-20. PMID 16384702 DOI: 10.1016/J.Bmcl.2005.12.004  0.419
2005 Olivero AG, Eigenbrot C, Goldsmith R, Robarge K, Artis DR, Flygare J, Rawson T, Sutherlin DP, Kadkhodayan S, Beresini M, Elliott LO, DeGuzman GG, Banner DW, Ultsch M, Marzec U, et al. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. The Journal of Biological Chemistry. 280: 9160-9. PMID 15632123 DOI: 10.1074/jbc.M409068200  0.317
2004 Lien S, Pastor R, Sutherlin D, Lowman HB. A substrate-phage approach for investigating caspase specificity. The Protein Journal. 23: 413-25. PMID 15517988 DOI: 10.1023/B:Jopc.0000039555.92058.51  0.377
2002 Castanedo GM, Sailes FC, Dubree NJ, Nicholas JB, Caris L, Clark K, Keating SM, Beresini MH, Chiu H, Fong S, Marsters JC, Jackson DY, Sutherlin DP. Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores. Bioorganic & Medicinal Chemistry Letters. 12: 2913-7. PMID 12270174  0.558
2002 Dubree NJ, Artis DR, Castanedo G, Marsters J, Sutherlin D, Caris L, Clark K, Keating SM, Beresini MH, Chiu H, Fong S, Lowman HB, Skelton NJ, Jackson DY. Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. Journal of Medicinal Chemistry. 45: 3451-7. PMID 12139455 DOI: 10.1021/Jm020033K  0.565
2002 Perez OD, Chang YT, Rosania G, Sutherlin D, Schultz PG. Inhibition and reversal of myogenic differentiation by purine-based microtubule assembly inhibitors. Chemistry & Biology. 9: 475-83. PMID 11983336 DOI: 10.1016/S1074-5521(02)00131-X  0.654
2000 Rosania GR, Chang YT, Perez O, Sutherlin D, Dong H, Lockhart DJ, Schultz PG. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nature Biotechnology. 18: 304-8. PMID 10700146 DOI: 10.1038/73753  0.669
1999 Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry & Biology. 6: 361-75. PMID 10375538 DOI: 10.1016/S1074-5521(99)80048-9  0.65
1998 Pedersen H, Hölder S, Sutherlin DP, Schwitter U, King DS, Schultz PG. A method for directed evolution and functional cloning of enzymes. Proceedings of the National Academy of Sciences of the United States of America. 95: 10523-8. PMID 9724736 DOI: 10.1073/Pnas.95.18.10523  0.541
Show low-probability matches.